Targeted Therapy

In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.

In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.

In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.

In these videos, Koyal Jain, MD, MPH, FASN, associate professor of medicine and director, nephrology and hypertension training program at UNC School of Medicin, discusses the latest advancements in glomerular diseases.

Survival for patients with metastatic colorectal cancer has improved steadily since 2012, according to retrospective study results.

Oncologists who treat non-Hodgkin lymphoma have increasingly become reliant on targeted treatment, with several new agents receiving FDA approval within the past 5 years.

The advent of novel therapies has propelled, and continues to propel, tremendous progress and innovation in diffuse large B-cell lymphoma.

CHICAGO — Healio spoke with Nikhil Wagle, MD, about his educational session on the role genomic profiling and treatment decisions in metastatic breast cancer at ASCO Annual Meeting.

The development of targeted cancer therapies has led to improved clinical outcomes for many patients. However, monotherapies against a single target can result in treatment resistance.